[ad_1]
why: Rosen Law Firm, a global investor rights law firm, reminded purchasers of BELLUS Health Inc. (NASDAQ:Blu-ray), the important date is between September 5, 2019 and July 5, 2020 (both dates inclusive) On May 17, 2021, the plaintiff takes the lead.
So: If you purchased Bellus securities during class, you may be entitled to compensation without having to pay any ready-made fees or costs through contingency fee arrangements.
What to do next: To participate in the Bellus class action, go to http://www.rosenlegal.com/cases-register-2058.html Or call Phillip Kim, Esq.Toll free 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com Information about class actions. A class action lawsuit has been filed.If you want to be the lead plaintiff, you must move the court No later than May 17, 2021. The lead plaintiff is the representative party in guiding the litigation on behalf of other class members.
Why Rosen Law: We encourage investors to choose qualified lawyers with successful leadership experience. Often, the company issuing the notice does not have comparable experience or resources. Lawson Law Firm represents global investors and is mainly engaged in securities class actions and shareholder derivatives litigation. Rosen Law Firm has completed the largest securities class action settlement against a Chinese company. Rosen Law Firm was ranked number one by ISS Securities Class Litigation Service in the 2017 ISS class action lawsuit. The firm has been in the top four each year since 2013 and has recovered hundreds of millions of dollars in earnings for investors. In 2019 alone, the company received more than $438 million in funding for investors. In 2020, the founding partner Laurence Rosen was named the Titan of the Plaintiff’s Bar by law360. Many of the company’s lawyers have been accredited by Lawdragon and Super Lawyers.
Case details: According to the lawsuit, during the entire class, the defendant made false and/or misleading statements, and/or failed to disclose information that led to the following plans: (1) In Bellus’ business, operations, drugs, and drug development, it defrauded the investing public and competed As well as current and future business prospects; (2) Promoted the company’s public offering in September 2019 (the “Offer”); (3) Artificial demand for BELLUS common stock sold in the issuance; (4) Enabling the company Able to obtain a net income of approximately US$70 million through the sale of BELLUS common stock issued this time; (5) Purchase of BELLUS publicly traded common stock at an artificially elevated price. When the real details entered the market, the lawsuit claimed that investors suffered losses.
To participate in the Bellus class action, go to http://www.rosenlegal.com/cases-register-2058.html Or call Phillip Kim, Esq.Toll free 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com Information about class actions.
No courses are accredited. Until the course is certified, you will not be represented by a lawyer unless you retain a lawyer. You can choose the lawyer of your choice. You may also be absent and do nothing at this time. The ability of investors to share potential future earnings does not depend on acting as the main plaintiff.
Follow us on LinkedIn for updates: https://www.linkedin.com/company/the-rosen-law-firm, On Twitter: https://twitter.com/rosen_firm Or on Facebook: https://www.facebook.com/rosenlawfirm/.
Lawyer advertisement. The previous results cannot guarantee similar results.
View the source code version on businesswire.com: https://www.businesswire.com/news/home/20210515005019/zh/
[ad_2]
Source link
